In early December 2025, Recursion Pharmaceuticals released clinical data from the TUPELO Phase 1b/2 trial of REC-4881, providing fresh insight into the candidate’s safety and efficacy profile. This ...

After twelve years at the helm of AI-drug developer Recursion, Chris Gibson will hand the CEO baton to Najat Khan, PhD, the company’s chief R&D officer and chief commercial officer, effective January ...

The new major version with a new JIT compiler, a revised parallelization API, and a maturing type system paves the way for ...

I've been testing PC and mobile software for more than 20 years, focusing on photo and video editing, operating systems, and web browsers. Prior to my current role, I covered software and apps for ...